Grzegorz Raczak

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Heart rate variability measures: a fresh look at reliability

Gian Domenico Pinna, Roberto Maestri, Antoni Toruński et al. · Clinical Science · 2007 · 259 citations · Full text

Medicine, Cardiology, Physiology +14

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Measuring baroreflex sensitivity from the gain function between arterial pressure and heart period

Gian Domenico Pinna, Roberto Maestri, Grzegorz Raczak et al. · Clinical Science · 2002 · 91 citations

Medicine, Cardiology, Physiology +17